Registry update — unassessed
Effect of Tirzepatide on Functional Outcomes in Patients With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy: A Multicenter, Randomized, Controlled, Blinded Outcome Assessment Trial
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 1, 2026 · Discovered: Oct 1, 2026 · Assessed: — · Research update
What it does not prove
- The abstract presents only the study protocol and rationale, not completed results, so no efficacy or safety findings can be extracted.
- The mechanism-based rationale (neuroprotection via inflammation and oxidative stress reduction) is theoretical; this study design tests functional outcomes but does not establish mechanisms.
- As a Phase II/proof-of-concept trial, results would not establish tirzepatide as standard care or prove benefit in all stroke populations without larger replication.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 3 months
- Population
- Patients with acute ischemic stroke caused by blockage of a large brain artery (large vessel occlusion) who are eligible for and undergoing endovascular thrombectomy
- Primary outcome
- Functional recovery at 90 days after stroke, measured by patient's ability to perform daily activities and live independently
- Effect size
- —
- Significance
- Not reported
- Journal
- yifang zhu
- Published
- Oct 1, 2026
Sources
Primary source
- yifang zhu ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This study aims to evaluate whether tirzepatide, a medication that activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) pathways, can improve recovery in patients with acute ischemic stroke caused by large vessel occlusion who receive thrombectomy.
In this study, eligible patients with acute ischemic stroke caused by blockage of a major brain artery will be randomly assigned to receive either tirzepatide plus standard stroke care or standard stroke care alone.
Participants will receive two subcutaneous injections of tirzepatide: the first dose before the thrombectomy procedure and the second dose 7 days after the procedure.
The primary purpose of this study is to determine whether early treatment with tirzepatide can improve functional recovery 90 days after stroke, measured by the patient's ability to perform daily activities and live independently.
The study will also evaluate whether tirzepatide is safe in patients with acute ischemic stroke by monitoring adverse events, complications, and other clinical outcomes.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.